Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database
While stage III and IV classical Hodgkin lymphoma (HL) patients are often combined and defined as “advanced stage,” there are significant differences in disease distribution and burden between the two stages. This may obscure advantages of radiotherapy (RT) in a combined modality therapy strategy in...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Bates, James E. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells - Han, Xiaobing ELSEVIER, 2021, journal of the European Society for Therapeutic Radiology and Oncology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:124 ; year:2017 ; number:2 ; pages:325-330 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.radonc.2017.07.016 |
|---|
| Katalog-ID: |
ELV014868210 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV014868210 | ||
| 003 | DE-627 | ||
| 005 | 20230623115943.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.radonc.2017.07.016 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017004000012.pica |
| 035 | |a (DE-627)ELV014868210 | ||
| 035 | |a (ELSEVIER)S0167-8140(17)32475-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 570 |a 540 |q VZ |
| 100 | 1 | |a Bates, James E. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database |
| 264 | 1 | |c 2017 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a While stage III and IV classical Hodgkin lymphoma (HL) patients are often combined and defined as “advanced stage,” there are significant differences in disease distribution and burden between the two stages. This may obscure advantages of radiotherapy (RT) in a combined modality therapy strategy in stage III disease due to the relative lack of benefit in stage IV patients. | ||
| 650 | 7 | |a SEER |2 Elsevier | |
| 650 | 7 | |a Radiotherapy |2 Elsevier | |
| 650 | 7 | |a Classical Hodgkin lymphoma |2 Elsevier | |
| 700 | 1 | |a Dhakal, Sughosh |4 oth | |
| 700 | 1 | |a Mazloom, Ali |4 oth | |
| 700 | 1 | |a Casulo, Carla |4 oth | |
| 700 | 1 | |a Constine, Louis S. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Han, Xiaobing ELSEVIER |t Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |d 2021 |d journal of the European Society for Therapeutic Radiology and Oncology |g Amsterdam [u.a.] |w (DE-627)ELV00004122X |
| 773 | 1 | 8 | |g volume:124 |g year:2017 |g number:2 |g pages:325-330 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.radonc.2017.07.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 124 |j 2017 |e 2 |h 325-330 |g 6 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
j e b je jeb |
|---|---|
| matchkey_str |
batesjamesedhakalsughoshmazloomalicasulo:2017----:eeifotenlsoordainhrpiteramnoptetwtsaeicasclogilmhmarpniyaceaayiote |
| hierarchy_sort_str |
2017 |
| publishDate |
2017 |
| allfields |
10.1016/j.radonc.2017.07.016 doi GBVA2017004000012.pica (DE-627)ELV014868210 (ELSEVIER)S0167-8140(17)32475-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Bates, James E. verfasserin aut Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database 2017 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier While stage III and IV classical Hodgkin lymphoma (HL) patients are often combined and defined as “advanced stage,” there are significant differences in disease distribution and burden between the two stages. This may obscure advantages of radiotherapy (RT) in a combined modality therapy strategy in stage III disease due to the relative lack of benefit in stage IV patients. SEER Elsevier Radiotherapy Elsevier Classical Hodgkin lymphoma Elsevier Dhakal, Sughosh oth Mazloom, Ali oth Casulo, Carla oth Constine, Louis S. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:124 year:2017 number:2 pages:325-330 extent:6 https://doi.org/10.1016/j.radonc.2017.07.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 124 2017 2 325-330 6 045F 610 |
| spelling |
10.1016/j.radonc.2017.07.016 doi GBVA2017004000012.pica (DE-627)ELV014868210 (ELSEVIER)S0167-8140(17)32475-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Bates, James E. verfasserin aut Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database 2017 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier While stage III and IV classical Hodgkin lymphoma (HL) patients are often combined and defined as “advanced stage,” there are significant differences in disease distribution and burden between the two stages. This may obscure advantages of radiotherapy (RT) in a combined modality therapy strategy in stage III disease due to the relative lack of benefit in stage IV patients. SEER Elsevier Radiotherapy Elsevier Classical Hodgkin lymphoma Elsevier Dhakal, Sughosh oth Mazloom, Ali oth Casulo, Carla oth Constine, Louis S. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:124 year:2017 number:2 pages:325-330 extent:6 https://doi.org/10.1016/j.radonc.2017.07.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 124 2017 2 325-330 6 045F 610 |
| allfields_unstemmed |
10.1016/j.radonc.2017.07.016 doi GBVA2017004000012.pica (DE-627)ELV014868210 (ELSEVIER)S0167-8140(17)32475-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Bates, James E. verfasserin aut Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database 2017 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier While stage III and IV classical Hodgkin lymphoma (HL) patients are often combined and defined as “advanced stage,” there are significant differences in disease distribution and burden between the two stages. This may obscure advantages of radiotherapy (RT) in a combined modality therapy strategy in stage III disease due to the relative lack of benefit in stage IV patients. SEER Elsevier Radiotherapy Elsevier Classical Hodgkin lymphoma Elsevier Dhakal, Sughosh oth Mazloom, Ali oth Casulo, Carla oth Constine, Louis S. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:124 year:2017 number:2 pages:325-330 extent:6 https://doi.org/10.1016/j.radonc.2017.07.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 124 2017 2 325-330 6 045F 610 |
| allfieldsGer |
10.1016/j.radonc.2017.07.016 doi GBVA2017004000012.pica (DE-627)ELV014868210 (ELSEVIER)S0167-8140(17)32475-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Bates, James E. verfasserin aut Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database 2017 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier While stage III and IV classical Hodgkin lymphoma (HL) patients are often combined and defined as “advanced stage,” there are significant differences in disease distribution and burden between the two stages. This may obscure advantages of radiotherapy (RT) in a combined modality therapy strategy in stage III disease due to the relative lack of benefit in stage IV patients. SEER Elsevier Radiotherapy Elsevier Classical Hodgkin lymphoma Elsevier Dhakal, Sughosh oth Mazloom, Ali oth Casulo, Carla oth Constine, Louis S. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:124 year:2017 number:2 pages:325-330 extent:6 https://doi.org/10.1016/j.radonc.2017.07.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 124 2017 2 325-330 6 045F 610 |
| allfieldsSound |
10.1016/j.radonc.2017.07.016 doi GBVA2017004000012.pica (DE-627)ELV014868210 (ELSEVIER)S0167-8140(17)32475-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Bates, James E. verfasserin aut Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database 2017 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier While stage III and IV classical Hodgkin lymphoma (HL) patients are often combined and defined as “advanced stage,” there are significant differences in disease distribution and burden between the two stages. This may obscure advantages of radiotherapy (RT) in a combined modality therapy strategy in stage III disease due to the relative lack of benefit in stage IV patients. SEER Elsevier Radiotherapy Elsevier Classical Hodgkin lymphoma Elsevier Dhakal, Sughosh oth Mazloom, Ali oth Casulo, Carla oth Constine, Louis S. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:124 year:2017 number:2 pages:325-330 extent:6 https://doi.org/10.1016/j.radonc.2017.07.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 124 2017 2 325-330 6 045F 610 |
| language |
English |
| source |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:124 year:2017 number:2 pages:325-330 extent:6 |
| sourceStr |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:124 year:2017 number:2 pages:325-330 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
SEER Radiotherapy Classical Hodgkin lymphoma |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| authorswithroles_txt_mv |
Bates, James E. @@aut@@ Dhakal, Sughosh @@oth@@ Mazloom, Ali @@oth@@ Casulo, Carla @@oth@@ Constine, Louis S. @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00004122X |
| dewey-sort |
3610 |
| id |
ELV014868210 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV014868210</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623115943.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2017.07.016</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017004000012.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV014868210</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(17)32475-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bates, James E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">While stage III and IV classical Hodgkin lymphoma (HL) patients are often combined and defined as “advanced stage,” there are significant differences in disease distribution and burden between the two stages. This may obscure advantages of radiotherapy (RT) in a combined modality therapy strategy in stage III disease due to the relative lack of benefit in stage IV patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SEER</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Classical Hodgkin lymphoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dhakal, Sughosh</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mazloom, Ali</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Casulo, Carla</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Constine, Louis S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:124</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:325-330</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2017.07.016</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">124</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">325-330</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Bates, James E. |
| spellingShingle |
Bates, James E. ddc 610 ddc 570 Elsevier SEER Elsevier Radiotherapy Elsevier Classical Hodgkin lymphoma Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database |
| authorStr |
Bates, James E. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00004122X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 570 540 VZ Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database SEER Elsevier Radiotherapy Elsevier Classical Hodgkin lymphoma Elsevier |
| topic |
ddc 610 ddc 570 Elsevier SEER Elsevier Radiotherapy Elsevier Classical Hodgkin lymphoma |
| topic_unstemmed |
ddc 610 ddc 570 Elsevier SEER Elsevier Radiotherapy Elsevier Classical Hodgkin lymphoma |
| topic_browse |
ddc 610 ddc 570 Elsevier SEER Elsevier Radiotherapy Elsevier Classical Hodgkin lymphoma |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s d sd a m am c c cc l s c ls lsc |
| hierarchy_parent_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| hierarchy_parent_id |
ELV00004122X |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00004122X |
| title |
Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database |
| ctrlnum |
(DE-627)ELV014868210 (ELSEVIER)S0167-8140(17)32475-1 |
| title_full |
Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database |
| author_sort |
Bates, James E. |
| journal |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| journalStr |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
325 |
| author_browse |
Bates, James E. |
| container_volume |
124 |
| physical |
6 |
| class |
610 610 DE-600 570 540 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Bates, James E. |
| doi_str_mv |
10.1016/j.radonc.2017.07.016 |
| dewey-full |
610 570 540 |
| title_sort |
benefit from the inclusion of radiation therapy in the treatment of patients with stage iii classical hodgkin lymphoma: a propensity matched analysis of the surveillance, epidemiology, and end results database |
| title_auth |
Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database |
| abstract |
While stage III and IV classical Hodgkin lymphoma (HL) patients are often combined and defined as “advanced stage,” there are significant differences in disease distribution and burden between the two stages. This may obscure advantages of radiotherapy (RT) in a combined modality therapy strategy in stage III disease due to the relative lack of benefit in stage IV patients. |
| abstractGer |
While stage III and IV classical Hodgkin lymphoma (HL) patients are often combined and defined as “advanced stage,” there are significant differences in disease distribution and burden between the two stages. This may obscure advantages of radiotherapy (RT) in a combined modality therapy strategy in stage III disease due to the relative lack of benefit in stage IV patients. |
| abstract_unstemmed |
While stage III and IV classical Hodgkin lymphoma (HL) patients are often combined and defined as “advanced stage,” there are significant differences in disease distribution and burden between the two stages. This may obscure advantages of radiotherapy (RT) in a combined modality therapy strategy in stage III disease due to the relative lack of benefit in stage IV patients. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
2 |
| title_short |
Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database |
| url |
https://doi.org/10.1016/j.radonc.2017.07.016 |
| remote_bool |
true |
| author2 |
Dhakal, Sughosh Mazloom, Ali Casulo, Carla Constine, Louis S. |
| author2Str |
Dhakal, Sughosh Mazloom, Ali Casulo, Carla Constine, Louis S. |
| ppnlink |
ELV00004122X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.radonc.2017.07.016 |
| up_date |
2024-07-06T22:41:54.787Z |
| _version_ |
1803871285189541888 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV014868210</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623115943.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2017.07.016</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017004000012.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV014868210</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(17)32475-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bates, James E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">While stage III and IV classical Hodgkin lymphoma (HL) patients are often combined and defined as “advanced stage,” there are significant differences in disease distribution and burden between the two stages. This may obscure advantages of radiotherapy (RT) in a combined modality therapy strategy in stage III disease due to the relative lack of benefit in stage IV patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SEER</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Classical Hodgkin lymphoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dhakal, Sughosh</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mazloom, Ali</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Casulo, Carla</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Constine, Louis S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:124</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:325-330</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2017.07.016</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">124</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">325-330</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.401039 |